Page 17 - Cassava Sciences News Today

Dublin, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The "Global Alzheimer's Disease Market 2023-2032" report has been added to ResearchAndMarkets.com's offering. Alzheimer's disease, a progressive neurodegenerative disorder, is on the rise due to the aging population and increased disease awareness. Advances in understanding its pathophysiology have led to the development of new diagnostic tools and therapeutic approaches. While the current treatment focuses on managing symptoms a...

New York, USA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Carpal Tunnel Release System Global Market to Showcase Growth at a CAGR of ~5% by 2028 | DelveInsight The global carpal tunnel release system market is expected

  On Tuesday, 210 companies reached new 52-week lows.

/PRNewswire/ -- DelveInsights Medical Second Opinion Market Insights report provides the current and forecast market analysis, individual leading medical...

/PRNewswire/ -- The "Alzheimers Disease - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering....

Our Focus is Alzheimers disease August 2023 Forward-Looking Statements & Safe...

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report) shares reached a new 52-week low on Monday . The company traded as low as $17.70 and last traded at $17.87, with a volume of 44589 shares traded. The stock had previously closed at $17.92. Wall Street Analyst Weigh In Separately, HC Wainwright reaffirmed a “buy” rating […]

  During the Friday's sesion, 157 stocks hit new 52-week lows.

Cassava Sciences Stock (NASDAQ: SAVA) stock price, news, charts, stock research, profile.

Cassava Sciences, Inc. (NASDAQ: SAVA) saw its shares descend Thursday, as the clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2023. Net loss was $26.4 million, ...